Advances in the management of pancreatic ductal adenocarcinoma

The incidence of pancreatic ductal adenocarcinoma (PDAC) is rising and PDAC is projected to become the third leading cause of cancer death in Canada. Although risk factors for PDAC are known, the reason for its rising incidence is not. Overall survival for this disease at 5 years has improved recent...

Full description

Saved in:
Bibliographic Details
Published inCanadian Medical Association journal (CMAJ) Vol. 193; no. 23; pp. E844 - E851
Main Authors O'Kane, Grainne M, Ladak, Farah, Gallinger, Steven
Format Journal Article
LanguageEnglish
Published Canada CMA Joule Inc 07.06.2021
CMA Impact, Inc
Subjects
Canada - epidemiology
Cancer therapies
Carcinoma, Pancreatic Ductal - diagnosis
Carcinoma, Pancreatic Ductal - epidemiology
Carcinoma, Pancreatic Ductal - therapy
Care and treatment
Chemotherapy
Chemotherapy, Adjuvant - methods
Diagnosis
Disease
Humans
Incidence
Pancreatic cancer
Patients
Radiation
Review
Risk factors
Surgery
Tumors
Veins & arteries
Canada
United States > US
Online AccessGet full text

Cover

More Information
Summary:The incidence of pancreatic ductal adenocarcinoma (PDAC) is rising and PDAC is projected to become the third leading cause of cancer death in Canada. Although risk factors for PDAC are known, the reason for its rising incidence is not. Overall survival for this disease at 5 years has improved recently; however, survival for other malignant diseases has improved more. A 2018 retrospective study of patients in Alberta found that more than 40% of patients with advanced PDAC were not referred for specialist care. Surgical resection remains the only opportunity to cure PDAC, and only 15%-20% of patients present with resectable disease. However, PDAC is a heterogenous disease and several useful genomic classifiers and RNA-based subtypes have been identified that are beginning to inform treatment strategies for patients with nonresectable disease, with some showing survival benefit. Here, O'Kane et al discuss evidence supporting the most recent clinical advances in treatment of PDAC.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0820-3946
1488-2329
DOI:10.1503/cmaj.201450